Literature DB >> 26315485

An integrated network platform for contextual prioritization of drugs and pathways.

Aldo Segura-Cabrera1, Navneet Singh, Kakajan Komurov.   

Abstract

Repurposing of drugs to novel disease indications has promise for faster clinical translation. However, identifying the best drugs for a given pathological context is not trivial. We developed an integrated random walk-based network framework that combines functional biomolecular relationships and known drug-target interactions as a platform for contextual prioritization of drugs, genes and pathways. We show that the use of gene-centric or drug-centric data, such as gene expression data or a phenotypic drug screen, respectively, within this network platform can effectively prioritize drugs and pathways, respectively, to the studied biological context. We demonstrate that various genomic data can be used as contextual cues to effectively prioritize drugs to the studied context, while similarly, phenotypic drug screen data can be used to effectively prioritize genes and pathways to the studied phenotypic context. As a proof-of-principle, we showcase the use of our platform to identify known and novel drug indications against different subsets of breast cancers through contextual prioritization based on genome-wide gene expression, shRNA and drug screen and clinical survival data. The integrated network and associated methods are incorporated into the NetWalker suite for functional genomics analysis ().

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26315485      PMCID: PMC4814269          DOI: 10.1039/c5mb00444f

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  62 in total

Review 1.  Unveiling the role of network and systems biology in drug discovery.

Authors:  Albert Pujol; Roberto Mosca; Judith Farrés; Patrick Aloy
Journal:  Trends Pharmacol Sci       Date:  2010-02-01       Impact factor: 14.819

Review 2.  Network pharmacology: the next paradigm in drug discovery.

Authors:  Andrew L Hopkins
Journal:  Nat Chem Biol       Date:  2008-11       Impact factor: 15.040

3.  Predicting new molecular targets for known drugs.

Authors:  Michael J Keiser; Vincent Setola; John J Irwin; Christian Laggner; Atheir I Abbas; Sandra J Hufeisen; Niels H Jensen; Michael B Kuijer; Roberto C Matos; Thuy B Tran; Ryan Whaley; Richard A Glennon; Jérôme Hert; Kelan L H Thomas; Douglas D Edwards; Brian K Shoichet; Bryan L Roth
Journal:  Nature       Date:  2009-11-01       Impact factor: 49.962

4.  Systematic evaluation of drug-disease relationships to identify leads for novel drug uses.

Authors:  A P Chiang; A J Butte
Journal:  Clin Pharmacol Ther       Date:  2009-07-01       Impact factor: 6.875

5.  Generating genome-scale candidate gene lists for pharmacogenomics.

Authors:  N T Hansen; S Brunak; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

6.  Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.

Authors:  Duane C Hassane; Monica L Guzman; Cheryl Corbett; Xiaojie Li; Ramzi Abboud; Fay Young; Jane L Liesveld; Martin Carroll; Craig T Jordan
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

7.  HMDB: a knowledgebase for the human metabolome.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Roman Eisner; Nelson Young; Bijaya Gautam; David D Hau; Nick Psychogios; Edison Dong; Souhaila Bouatra; Rupasri Mandal; Igor Sinelnikov; Jianguo Xia; Leslie Jia; Joseph A Cruz; Emilia Lim; Constance A Sobsey; Savita Shrivastava; Paul Huang; Philip Liu; Lydia Fang; Jun Peng; Ryan Fradette; Dean Cheng; Dan Tzur; Melisa Clements; Avalyn Lewis; Andrea De Souza; Azaret Zuniga; Margot Dawe; Yeping Xiong; Derrick Clive; Russ Greiner; Alsu Nazyrova; Rustem Shaykhutdinov; Liang Li; Hans J Vogel; Ian Forsythe
Journal:  Nucleic Acids Res       Date:  2008-10-25       Impact factor: 16.971

8.  Human disease-drug network based on genomic expression profiles.

Authors:  Guanghui Hu; Pankaj Agarwal
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

9.  Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.

Authors:  Li Xie; Jerry Li; Lei Xie; Philip E Bourne
Journal:  PLoS Comput Biol       Date:  2009-05-15       Impact factor: 4.475

10.  ORegAnno: an open-access community-driven resource for regulatory annotation.

Authors:  Obi L Griffith; Stephen B Montgomery; Bridget Bernier; Bryan Chu; Katayoon Kasaian; Stein Aerts; Shaun Mahony; Monica C Sleumer; Mikhail Bilenky; Maximilian Haeussler; Malachi Griffith; Steven M Gallo; Belinda Giardine; Bart Hooghe; Peter Van Loo; Enrique Blanco; Amy Ticoll; Stuart Lithwick; Elodie Portales-Casamar; Ian J Donaldson; Gordon Robertson; Claes Wadelius; Pieter De Bleser; Dominique Vlieghe; Marc S Halfon; Wyeth Wasserman; Ross Hardison; Casey M Bergman; Steven J M Jones
Journal:  Nucleic Acids Res       Date:  2007-11-15       Impact factor: 16.971

View more
  3 in total

Review 1.  Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases.

Authors:  Yuhei Nishimura; Hideaki Hara
Journal:  Oxid Med Cell Longev       Date:  2016-12-07       Impact factor: 6.543

2.  A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase.

Authors:  Aldo Segura-Cabrera; Reshmi Tripathi; Xiaoyi Zhang; Lin Gui; Tsui-Fen Chou; Kakajan Komurov
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

3.  Network-based modeling of drug effects on disease module in systemic sclerosis.

Authors:  Ki-Jo Kim; Su-Jin Moon; Kyung-Su Park; Ilias Tagkopoulos
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.